Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
40 participants
INTERVENTIONAL
2012-03-31
2013-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Control
The patients with symptomatic heart failure were treated with standard treatment.
No interventions assigned to this group
15 mg prednisone group
The patients with symptomatic heart failure are treated with prednisone at dose of 15 mg/day.
prednisone
The patients with symptomatic heart failure are treated with prednisone at dose of 15 mg/day.
30 mg prednisone group
The patients with symptomatic heart failure are treated with prednisone at dose of 30 mg/day.
prednisone
The patients with symptomatic heart failure are treated with prednisone at dose of 30 mg/day
60 mg prednisone group
The patients with symptomatic heart failure are treated with prednisone at dose of 60 mg/day.
prednisone
The patients with symptomatic heart failure are treated with prednisone at dose of 60 mg/day
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
prednisone
The patients with symptomatic heart failure are treated with prednisone at dose of 15 mg/day.
prednisone
The patients with symptomatic heart failure are treated with prednisone at dose of 30 mg/day
prednisone
The patients with symptomatic heart failure are treated with prednisone at dose of 60 mg/day
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* dyspnea at rest or with minimal activity
* NT-proBNP \> 1000pg/ml
* LVEF ≤ 40%
Exclusion Criteria
* acute decompensated heart failure
* active myocarditis
* obstructive or restrictive cardiomyopathy
* cardiac surgery within previous 3 months
* acute coronary syndrome
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hebei Medical University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Kun-shen Liu M.D.
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kunshen Liu, MD
Role: PRINCIPAL_INVESTIGATOR
The First Hospital of Hebei Medical University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The First Hospital of Hebei Medical University
Shijiazhuang, Hebei, China
The First Hospital of Hebei Medical University
Shijiazhuang, , China
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Liu C, Zhao Q, Zhen Y, Zhai J, Liu G, Zheng M, Ma G, Wang L, Tian L, Ji L, Li L, Duan L, Liu K. Effect of Corticosteroid on Renal Water and Sodium Excretion in Symptomatic Heart Failure: Prednisone for Renal Function Improvement Evaluation Study. J Cardiovasc Pharmacol. 2015 Sep;66(3):316-22. doi: 10.1097/FJC.0000000000000282.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GL-2011-29
Identifier Type: -
Identifier Source: org_study_id